BLUDIGO
Peakindigotindisulfonate sodium
NDAINTRAVENOUSSOLUTION
Approved
Jul 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
BLUDIGO (indigotindisulfonate sodium) is 12. First approved in 2022.
Drug data last refreshed 12h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLUDIGO (indigotindisulfonate sodium) is an intravenous diagnostic dye that enhances visualization of ureteral orifices during urological procedures through its deep blue color. The agent is excreted by the kidney via tubular secretion and becomes detectable at the ureteral orifices within 4–9 minutes of IV injection. It is used as an adjunct diagnostic tool in cystoscopy and related urological interventions.
Peak11.2 years to LOE
Early-stage peak commercial opportunity with zero reported competitive pressure suggests market dominance, but niche indication limits team scale and headcount growth potential.
Mechanism of Action
12.1 Mechanism of Action Indigotindisulfonate is a dye excreted by the kidney through tubular secretion and enhances visualization of the ureteral orifices by its deep blue color. 12.2 Pharmacodynamics The blue color is detectable at the ureteral orifices within 4 minutes to 9 minutes after the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BLUDIGO currently shows zero linked job openings, reflecting its niche market position and small commercial footprint. Roles supporting this product will center on urology-focused sales, medical education, and brand management rather than large-scale development or manufacturing teams.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.